MET and breast cancer: In order to validate that MET-CD47 co-expression is linked to dismal outcome and metastasis in vivo, we first re-analyzed the previously generated flow cytometry (FACS) data of luminal-type metastatic breast cancer patient CTCs for the specific presence of double positive MET+CD47+ CTCs [41].